Jeffrey Klem, MD
Cardiovascular Disease · Cleveland, TXNPI 1366448573
Payments from drug & device makers
Across 96 payments — averaging $63.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Boston Scientific$997
- Philips North America LLC$197
- Shockwave Medical, Inc$182
- Amgen$171
- Actelion Pharmaceuticals US, Inc.$158
- plus $1K from 19 others
What the payments were for
- Travel & lodging$3,04750%
- Food & beverage$3,00749%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 29 | $3,173 |
| Boston Scientific | 10 | $997 |
| Philips North America LLC | 3 | $197 |
| Shockwave Medical, Inc | 4 | $182 |
| Amgen | 2 | $171 |
| Actelion Pharmaceuticals US, Inc. | 6 | $158 |
| Inspire Medical Systems, Inc. | 1 | $152 |
| Johnson & Johnson | 2 | $137 |
| Biotronik Inc. | 1 | $130 |
| Sanofi | 1 | $117 |
| Angiodynamics, Inc. | 5 | $104 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $94 |
| Merck | 4 | $84 |
| Cordis US CORP. | 3 | $82 |
| Kestra Medical Technology Services, Inc. | 3 | $76 |
| AstraZeneca | 3 | $50 |
| Scpharmaceuticals Inc. | 2 | $32 |
| Bard Peripheral Vascular, Inc. | 1 | $25 |
| Recor Medical Inc | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Terumo Medical Corporation | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| United Therapeutics Corporation | 1 | $16 |
| Genentech USA, Inc. | 1 | $14 |
| Foundation Fusion Solutions, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELLIPSYS VASCULAR ACCESS SYSTEM$2,302
- JETSTREAM$679
- INTELLIS ADAPTIVESTIM$157
- Inspire$152
- AMVIA EDGE$130
- Renamic Neo$130
- BioMonitor$130
- (9520) IGT Devices Undivided$120
- XARELTO$120
How this compares
$6,082 in reported general payments places this provider in the 60th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 16 | $11,201 |
| Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide | 18 | $344 |
| Metoprolol Tartrate | 32 | $230 |
| ClopidogrelClopidogrel Bisulfate | 11 | $97 |
| Clonazepam | 15 | $78 |
| Atorvastatin Calcium | 11 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $137 | $11,20116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Cleveland
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.